Pharmacological treatment modalities such as glucagon-like peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors have become increasingly accepted as viable antidiabetic treatment options due to their safety and favorable cardiovascular profiles [9, 10]
The role of potassium in carcinogenesis is still not fully understood
Alcune formulazioni, come la tirzepatide, combinano questi due meccanismi, mentre altre, come la retatrutide, aggiungono un'azione sul glucagone, formando un triplo agonista
For example, caffeine and alcohol have been shown to reduce its effectiveness
It is unclear when that will happen, but even if it were soon, it would not pose much of an obstacle